Subsequent events	9 Months Ended
Mar. 27, 2026
Subsequent Events [Abstract]
Subsequent events	Subsequent events On March 25, 2026, the Company entered into a share purchase agreement to acquire a 16.0% equity interest in Raytek Semiconductor, Inc. (“Raytek”) for a total purchase price of approximately New Taiwan Dollar ("NT$") 1.02 billion ($32.4 million), subject to customary closing conditions. No amounts related to the investment have been recognized in the accompanying condensed consolidated financial statements for the three and nine months ended March 27, 2026 because the transaction was completed after the fiscal quarter ended. The Company evaluated the investment under ASC 323, Investments—Equity Method and Joint Ventures, and determined that it does not have significant influence over Raytek's operating and financial policies. Accordingly, the investment is not accounted for under the equity method and instead falls within the scope of ASC 321, Investments—Equity Securities. The Company will account for this investment at cost, subject to adjustments for observable price changes and impairment, as the investment does not have a readily determinable fair value.

Subsequent events

9 Months Ended

Mar. 27, 2026

On March 25, 2026, the Company entered into a share purchase agreement to acquire a 16.0% equity interest in Raytek Semiconductor, Inc. (“Raytek”) for a total purchase price of approximately New Taiwan Dollar ("NT$") 1.02 billion ($32.4 million), subject to customary closing conditions. No amounts related to the investment have been recognized in the accompanying condensed consolidated financial statements for the three and nine months ended March 27, 2026 because the transaction was completed after the fiscal quarter ended.

The Company evaluated the investment under ASC 323, Investments—Equity Method and Joint Ventures, and determined that it does not have significant influence over Raytek's operating and financial policies. Accordingly, the investment is not accounted for under the equity method and instead falls within the scope of ASC 321, Investments—Equity Securities. The Company will account for this investment at cost, subject to adjustments for observable price changes and impairment, as the investment does not have a readily determinable fair value.